Drug Trial Radar · NCT02554812
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Last checked: Nov 19, 2026Latest source record: Jul 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
409
Actual
Start
Nov 9, 2015
Primary completion
Mar 23, 2023
Study completion Mar 23, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.
Conditions
- Advanced Cancer
Interventions
AvelumabDrug
Anti-PD-L1 antibody
UtomilumabDrug
Anti-4-1BB antibody
PF-04518600Drug
OX40 Agonist
PD 0360324Drug
Anti-M-CSF
CMP-001Drug
TLR9 agonist
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b Lead-in: Number of Participants With First 2 Cycles Dose Limiting Toxicity (DLT) for Combination ATime frame: Baseline up to Cycle 2 (up to 8 weeks)
- Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination BTime frame: Baseline up to Cycle 2 (up to 8 weeks)
- Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination CTime frame: Baseline up to Cycle 2 (up to 8 weeks)
- Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination DTime frame: Baseline up to Cycle 2 (up to 8 weeks)
- Phase 1b Lead-in: Number of Participants With First Cycle DLT for Combination FTime frame: Baseline up to first Cycle (up to 4 weeks)
- Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment for Combination ATime frame: From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 53 months approximately)
- Phase 2: Percentage of Participants With Confirmed OR as Per RECIST v 1.1 by Investigator Assessment for Combination BTime frame: From start of the treatment until disease progression or death due to any cause, whichever occurred first (approximately 26 months)
Locations
88 sites in 8 countries. Site status is shown where the registry gives one.
UCSD Medical Center - Encinitas
Encinitas, California
Koman Family Outpatient Pavilion
La Jolla, California
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
La Jolla, California
UC San Diego Perlman Medical Offices
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
UCLA Clinical Research Unit (Adminstration Office)
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Hematology-Oncology Clinic
Los Angeles, California
UCLA Hematology-Oncology Infusion Center
Los Angeles, California
UC San Diego Medical Center - Hillcrest
San Diego, California
UCSD Medical Center - Vista
Vista, California
Georgetown University Medical Center
Washington D.C., District of Columbia
Mount Sinai Comprehensive Cancer Center - Aventura
Aventura, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Florida Cancer Specialists
Sarasota, Florida
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Michigan Hospitals
Ann Arbor, Michigan
University of Michigan
Ann Arbor, Michigan
Investigational Pharmacy, Karmanos Cancer Center
Detroit, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Karmanos Cancer Institute Weisberg Cancer Treatment Center
Farmington Hills, Michigan
VA NY Harbor Healthcare System
New York, New York
NYU Investigational Pharmacy
New York, New York
NYU Langone Medical Center
New York, New York
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York
Weill Cornell Medical College
New York, New York
Research Pharmacy #PH#
New York, New York
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York
Sampson Regional Medical Center
Clinton, North Carolina
Southeastern Medical Oncology Center
Clinton, North Carolina
Southeastern Medical Oncology Center
Goldsboro, North Carolina
Wayne Memorial Hospital
Goldsboro, North Carolina
Onslow Memorial Hospital
Jacksonville, North Carolina
Southeastern Medical Oncology Center
Jacksonville, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
UPCI Investigational Drug Service
Pittsburgh, Pennsylvania
UPMC Shadyside Hospital
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.